Loco, it's great to be objective...but not stupid! You saw the lack of pps movement on the previous two positive PRs. The market is waiting for news of potential revenue rather than data. The LymPro launch only began a week ago, a day or so before Christmas. You can't expect AMBS to sign up pharmas who want to use Lympro in that short a time. The middle of January makes more sense for the release of the data, because it gives AMBS a chance to couple the Lympro data with sales news....thus increasing the meaningfulness and potency of the data release.
Holding Gerald to his promise to release the data by year end, even if it makes more sense for him to release it just 2 weeks later.....makes you come off unreasonable for being so critical.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links